MedTrace Logo

Scleroligation for Eradication of Gastroesophageal Varices.

NCT02646202 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2017-12-27

No results posted yet for this study

Summary

Gastric varices occur in 5-33% of patients with portal hypertension. Concomitant gastro esophageal varices are the most common type. Both endoscopic sclerotherapy and band ligation are very effective in controlling acute esophageal varices bleeding and preventing rebleeding.

Conditions

  • Gastroesophageal Varices

Interventions

PROCEDURE

Sclerotherapy

Injection of varices

PROCEDURE

Band ligation

endoscopic banding of varices

PROCEDURE

Scleroligation

intra variceal endoscopic sclerotherapy combined with band ligation.

Sponsors & Collaborators

  • Tanta University

    collaborator OTHER

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Ferial El-kalla, Professor · Head of endoscopy unit - Tropical medicine department- Tanta

  • Mohamed Elhendawy, Consultant · liver diseases dept.- Tanta university hospital

  • Loai Mansour, Consultant · liver diseases dept.-Tanta university hospital

  • Abdelrahman kobtan, Consultant · liver diseases dept.-Tanta university hospital

  • Rehab Badawy, Consultant · liver diseases dept.-Tanta university hospital

  • Hanan Elbasat, Professor · liver diseases dept.-Tanta university hospital

  • Sherief Abd-Elsalam, Consultant · Liver diseases and gastroenterology dept.-Tanta university hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02646202 on ClinicalTrials.gov